HCPCS Code J7513

Daclizumab, parenteral, 25 mg
Code effective Jan 01, 2026

HCPCS Section
Drugs administered other than oral method, chemotherapy drugs

J7513 is a valid 2026 HCPCS code meaning Daclizumab, parenteral, 25 mg or (Daclizumab, parenteral) for short. HCPCS J7513 has been effective since 01/01/2026 and applies to Medical care.

HCPCS Code Details - J7513

HCPCS Level II Code
Section J - Drugs administered other than oral method, chemotherapy drugs
HCPCS Code J7513
Description

Long description:
Daclizumab, parenteral, 25 mg

Short description:
Daclizumab, parenteral

HCPCS Pricing indicator 51 - Drugs
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Coverage code D - Special coverage instructions apply
BETOS2 code O1E - Other drugs
HCPCS Action code N - No maintenance for this code
Type of service 1 - Medical care
Effective date Effective Jan 01, 2026
Date added Added Jan 01, 1999
Termination date Dec 31, 2025

See also

  • HCPCS J7512 · Prednisone, immediate release or delayed release, oral, 1 mg

  • HCPCS J7514 · Mycophenolate mofetil (myhibbin), oral suspension, 100 mg

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.